Monte Rosa Therapeutics, Inc. Financials
This page shows Monte Rosa Therapeutics, Inc. (GLUE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 shows a revenue-funded narrowing of operating losses, but cash still behaves like a financed resource rather than a self-renewing one.
Better reported economics did not improve cash generation: revenue rose to$123.7M and net loss nearly halved to-$38.6M in FY2025, yet operating cash flow fell back to-$22.8M from$42.0M in FY2024. That gap implies FY2024’s positive cash flow was not the start of durable self-funding, while FY2025’s operating margin of-43.8% shows revenue scale absorbed more of a still-rising R&D base rather than improvement driven by austerity.
Short-term liquidity improved for a balance-sheet reason, not a cash-build reason: the current ratio jumped to 6.1x from 2.4x even though cash fell to
The company still runs an investment-heavy operating model: FY2025 R&D reached
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Monte Rosa Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Monte Rosa Therapeutics, Inc. has an operating margin of -43.8%, meaning the company retains $-44 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -107.3% the prior year.
Monte Rosa Therapeutics, Inc. carries a low D/E ratio of 0.93, meaning only $0.93 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 83/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 6.12, Monte Rosa Therapeutics, Inc. holds $6.12 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Monte Rosa Therapeutics, Inc. generated -$22.8M in operating cash flow, capex of $4.7M consumed most of it, leaving -$27.5M in free cash flow. This results in a low score of 37/100, reflecting heavy capital investment rather than weak cash generation.
Monte Rosa Therapeutics, Inc. generates a -16.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -32.6% the prior year.
Monte Rosa Therapeutics, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Monte Rosa Therapeutics, Inc. generates $0.59 in operating cash flow (-$22.8M OCF vs -$38.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Monte Rosa Therapeutics, Inc. generated $123.7M in revenue in fiscal year 2025. This represents an increase of 63.5% from the prior year.
Monte Rosa Therapeutics, Inc.'s EBITDA was -$43.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 38.8% from the prior year.
Monte Rosa Therapeutics, Inc. reported -$38.6M in net income in fiscal year 2025. This represents an increase of 46.9% from the prior year.
Monte Rosa Therapeutics, Inc. earned $-0.46 per diluted share (EPS) in fiscal year 2025. This represents an increase of 53.1% from the prior year.
Cash & Balance Sheet
Monte Rosa Therapeutics, Inc. generated -$27.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 172.3% from the prior year.
Monte Rosa Therapeutics, Inc. held $129.9M in cash against $0 in long-term debt as of fiscal year 2025.
Monte Rosa Therapeutics, Inc. had 66M shares outstanding in fiscal year 2025. This represents an increase of 6.6% from the prior year.
Margins & Returns
Monte Rosa Therapeutics, Inc.'s operating margin was -43.8% in fiscal year 2025, reflecting core business profitability. This is up 63.4 percentage points from the prior year.
Monte Rosa Therapeutics, Inc.'s net profit margin was -31.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 64.9 percentage points from the prior year.
Monte Rosa Therapeutics, Inc.'s ROE was -16.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 16.1 percentage points from the prior year.
Capital Allocation
Monte Rosa Therapeutics, Inc. invested $141.5M in research and development in fiscal year 2025. This represents an increase of 16.4% from the prior year.
Monte Rosa Therapeutics, Inc. invested $4.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 17.9% from the prior year.
GLUE Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.2M+51.4% | $2.8M-78.2% | $12.8M-45.0% | $23.2M-72.7% | $84.9M+40.0% | $60.6M+558.1% | $9.2M+96.3% | $4.7M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $44.1M+5.0% | $42.0M+14.5% | $36.7M+19.7% | $30.7M-4.8% | $32.2M-17.2% | $38.9M+40.7% | $27.6M-1.6% | $28.1M |
| SG&A Expenses | $10.2M-3.3% | $10.5M+16.0% | $9.1M+12.0% | $8.1M-7.0% | $8.7M-0.8% | $8.8M+8.0% | $8.1M-12.4% | $9.3M |
| Operating Income | -$50.0M-0.6% | -$49.7M-50.8% | -$33.0M-112.0% | -$15.6M-135.3% | $44.0M+238.6% | $13.0M+149.0% | -$26.5M+18.7% | -$32.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $52K-11.9% | $59K+101.9% | -$3.2M-365.0% | $1.2M+45.9% | $822K-62.0% | $2.2M+2947.9% | $71K-71.8% | $252K |
| Net Income | -$44.5M+3.5% | -$46.1M-70.3% | -$27.1M-120.3% | -$12.3M-126.2% | $46.9M+248.9% | $13.4M+156.3% | -$23.9M+21.3% | -$30.3M |
| EPS (Diluted) | $-0.45 | N/A | $-0.33-120.0% | $-0.15-126.3% | $0.57 | N/A | $-0.29+32.6% | $-0.43 |
GLUE Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $736.4M+64.1% | $448.7M-2.4% | $459.8M+27.9% | $359.6M-8.5% | $393.2M-10.4% | $438.7M+39.2% | $315.1M-8.4% | $344.1M |
| Current Assets | $677.5M+72.3% | $393.2M-2.1% | $401.8M+34.2% | $299.5M-9.9% | $332.3M-12.0% | $377.4M+50.3% | $251.2M-9.6% | $277.9M |
| Cash & Equivalents | $159.9M+23.1% | $129.9M-37.7% | $208.3M+200.1% | $69.4M-11.6% | $78.5M-65.0% | $224.3M+78.6% | $125.6M+15.4% | $108.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $9.0M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $214.5M-0.5% | $215.6M+0.7% | $214.0M+133.9% | $91.5M-22.5% | $118.0M-45.3% | $215.8M+96.9% | $109.6M-8.2% | $119.4M |
| Current Liabilities | $71.0M+10.6% | $64.2M+4.5% | $61.4M+46.8% | $41.9M-29.3% | $59.2M-62.3% | $156.9M+276.9% | $41.6M-1.7% | $42.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $521.9M+123.9% | $233.1M-5.2% | $245.8M-8.3% | $268.1M-2.6% | $275.2M+23.4% | $222.9M+8.5% | $205.5M-8.6% | $224.7M |
| Retained Earnings | -$521.7M-9.3% | -$477.2M-10.7% | -$431.1M-6.7% | -$404.0M-3.1% | -$391.7M+10.7% | -$438.6M+3.0% | -$452.0M-5.6% | -$428.2M |
GLUE Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$37.4M+13.1% | -$43.0M-142.8% | $100.4M+389.3% | -$34.7M+23.7% | -$45.5M-135.3% | $128.9M+714.1% | -$21.0M+24.4% | -$27.8M |
| Capital Expenditures | $1.9M+143.5% | $767K+17.8% | $651K-61.6% | $1.7M+6.8% | $1.6M+767.2% | $183K-54.1% | $399K-80.3% | $2.0M |
| Free Cash Flow | -$39.2M+10.4% | -$43.8M-143.9% | $99.8M+374.0% | -$36.4M+22.7% | -$47.1M-136.6% | $128.7M+701.8% | -$21.4M+28.2% | -$29.8M |
| Investing Cash Flow | -$261.0M-301.1% | -$65.1M-270.6% | $38.1M+50.6% | $25.3M+125.3% | -$100.2M-224.4% | -$30.9M-181.8% | $37.7M+161.7% | -$61.2M |
| Financing Cash Flow | $328.3M+1008.3% | $29.6M+8412.6% | $348K-4.7% | $365K+2507.1% | $14K-97.7% | $608K+3953.3% | $15K-100.0% | $98.0M |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
GLUE Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1188.5%+599.2pp | -1787.7%-1529.4pp | -258.3%-191.2pp | -67.1%-118.9pp | 51.8%+30.4pp | 21.4%+309.3pp | -287.8%+407.4pp | -695.3% |
| Net Margin | -1057.1%+600.9pp | -1658.0%-1445.9pp | -212.1%-159.1pp | -53.0%-108.2pp | 55.2%+33.0pp | 22.2%+281.1pp | -258.9%+386.7pp | -645.6% |
| Return on Equity | -8.5%+11.3pp | -19.8%-8.8pp | -11.0%-6.4pp | -4.6%-21.6pp | 17.0%+11.0pp | 6.0%+17.6pp | -11.6%+1.9pp | -13.5% |
| Return on Assets | -6.0%+4.2pp | -10.3%-4.4pp | -5.9%-2.5pp | -3.4%-15.3pp | 11.9%+8.9pp | 3.1%+10.6pp | -7.6%+1.2pp | -8.8% |
| Current Ratio | 9.54+3.4 | 6.12-0.4 | 6.54-0.6 | 7.16+1.5 | 5.61+3.2 | 2.40-3.6 | 6.03-0.5 | 6.56 |
| Debt-to-Equity | 0.41-0.5 | 0.93+0.1 | 0.87+0.5 | 0.34-0.1 | 0.43-0.5 | 0.97+0.4 | 0.530.0 | 0.53 |
| FCF Margin | -932.0%+642.3pp | -1574.3%-2355.8pp | 781.5%+938.5pp | -157.0%-101.6pp | -55.4%-267.7pp | 212.3%+444.4pp | -232.1%+402.4pp | -634.5% |
Similar Companies
Frequently Asked Questions
What is Monte Rosa Therapeutics, Inc.'s annual revenue?
Monte Rosa Therapeutics, Inc. (GLUE) reported $123.7M in total revenue for fiscal year 2025. This represents a 63.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Monte Rosa Therapeutics, Inc.'s revenue growing?
Monte Rosa Therapeutics, Inc. (GLUE) revenue grew by 63.5% year-over-year, from $75.6M to $123.7M in fiscal year 2025.
Is Monte Rosa Therapeutics, Inc. profitable?
No, Monte Rosa Therapeutics, Inc. (GLUE) reported a net income of -$38.6M in fiscal year 2025, with a net profit margin of -31.2%.
What is Monte Rosa Therapeutics, Inc.'s EBITDA?
Monte Rosa Therapeutics, Inc. (GLUE) had EBITDA of -$43.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Monte Rosa Therapeutics, Inc.'s operating margin?
Monte Rosa Therapeutics, Inc. (GLUE) had an operating margin of -43.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Monte Rosa Therapeutics, Inc.'s net profit margin?
Monte Rosa Therapeutics, Inc. (GLUE) had a net profit margin of -31.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Monte Rosa Therapeutics, Inc.'s return on equity (ROE)?
Monte Rosa Therapeutics, Inc. (GLUE) has a return on equity of -16.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Monte Rosa Therapeutics, Inc.'s free cash flow?
Monte Rosa Therapeutics, Inc. (GLUE) generated -$27.5M in free cash flow during fiscal year 2025. This represents a -172.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Monte Rosa Therapeutics, Inc.'s operating cash flow?
Monte Rosa Therapeutics, Inc. (GLUE) generated -$22.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Monte Rosa Therapeutics, Inc.'s total assets?
Monte Rosa Therapeutics, Inc. (GLUE) had $448.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Monte Rosa Therapeutics, Inc.'s capital expenditures?
Monte Rosa Therapeutics, Inc. (GLUE) invested $4.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Monte Rosa Therapeutics, Inc. spend on research and development?
Monte Rosa Therapeutics, Inc. (GLUE) invested $141.5M in research and development during fiscal year 2025.
What is Monte Rosa Therapeutics, Inc.'s current ratio?
Monte Rosa Therapeutics, Inc. (GLUE) had a current ratio of 6.12 as of fiscal year 2025, which is generally considered healthy.
What is Monte Rosa Therapeutics, Inc.'s debt-to-equity ratio?
Monte Rosa Therapeutics, Inc. (GLUE) had a debt-to-equity ratio of 0.93 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Monte Rosa Therapeutics, Inc.'s return on assets (ROA)?
Monte Rosa Therapeutics, Inc. (GLUE) had a return on assets of -8.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Monte Rosa Therapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Monte Rosa Therapeutics, Inc. (GLUE) had $129.9M in cash against an annual operating cash burn of $22.8M. This gives an estimated cash runway of approximately 68 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Monte Rosa Therapeutics, Inc.'s Piotroski F-Score?
Monte Rosa Therapeutics, Inc. (GLUE) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Monte Rosa Therapeutics, Inc.'s earnings high quality?
Monte Rosa Therapeutics, Inc. (GLUE) has an earnings quality ratio of 0.59x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Monte Rosa Therapeutics, Inc.?
Monte Rosa Therapeutics, Inc. (GLUE) scores 37 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.